AQST executive shares withheld for RSU taxes

Aquestive Therapeutics Corporate Secretary reports routine tax withholding transaction.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Aquestive Therapeutics Corporate Secretary reports routine tax withholding transaction. On the disposition date, 135,690 shares of common stock were withheld by the company to cover Lori J. Braender’s tax withholding obligation related to vesting Restricted Stock Units. After this non-market transaction, she directly holds 231,042 shares of common stock.

Insider Trade Summary

Exercise Price or Tax Liability: 135,690 shares

Exercise Price or Tax Liability 1 txn

Insider BRAENDER LORI J

Role Corporate Secretary

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	135,690	$4.23	$574K

Holdings After Transaction: Common Stock — 231,042 shares (Direct)

Footnotes (1)

F1. Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person.

Key Figures

Shares withheld for taxes: 135,690 shares Price per share reference: $4.23 per share Shares held after transaction: 231,042 shares

3 metrics

Shares withheld for taxes 135,690 shares Common stock withheld to satisfy RSU tax withholding obligation

Price per share reference $4.23 per share Value used for the tax-withholding disposition of common stock

Shares held after transaction 231,042 shares Direct common stock ownership by Lori J. Braender following withholding

Key Terms

Restricted Stock Units ("RSUs"), tax withholding obligation, Form 4

3 terms

Restricted Stock Units ("RSUs") financial

"vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

tax withholding obligation financial

"withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting"

Form 4 financial

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AQST report for Lori J. Braender?

Aquestive Therapeutics reported a tax-withholding disposition for Corporate Secretary Lori J. Braender. The company withheld 135,690 common shares to cover taxes due on vesting Restricted Stock Units that had been previously granted to her.

Was the AQST insider transaction an open-market sale of shares?

No, the transaction was not an open-market sale. Shares were withheld by Aquestive Therapeutics to satisfy Lori J. Braender’s tax obligation from RSU vesting, which is a routine administrative event rather than a discretionary stock sale in the market.

How many AQST shares were withheld for taxes in this Form 4?

A total of 135,690 shares of Aquestive Therapeutics common stock were withheld. These shares covered the reporting person’s tax withholding obligation arising from the vesting of previously granted Restricted Stock Units under the company’s equity compensation arrangements.

How many AQST shares does Lori J. Braender hold after this transaction?

Following the tax-withholding disposition, Lori J. Braender directly holds 231,042 shares of Aquestive Therapeutics common stock. This figure reflects her remaining direct ownership after the company withheld shares to cover the tax obligation associated with RSU vesting.

What does transaction code F mean in the AQST Form 4 filing?

Transaction code F indicates a disposition of shares to pay the exercise price or tax liability. In this AQST filing, it represents shares withheld by the issuer to satisfy the reporting person’s tax withholding obligation tied to vesting Restricted Stock Units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/11/2026 - 04:35 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BRAENDER LORI J

(Last)

(First)

(Middle)

C/O AQUESTIVE THERAPEUTICS, INC.

30 TECHNOLOGY DRIVE

(Street)

WARREN

NEW JERSEY

07059

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aquestive Therapeutics, Inc. [ AQST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Corporate Secretary

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/07/2026		F		135,690⁽¹⁾	D	$4.23	231,042	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person.

Remarks:

Former Chief Legal Officer and Chief Compliance Officer

	/s/ Thomas Zalewski, as Attorney-In-Fact	05/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR